<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00686400</url>
  </required_header>
  <id_info>
    <org_study_id>07R-1815, SMRI</org_study_id>
    <nct_id>NCT00686400</nct_id>
  </id_info>
  <brief_title>A German Multicenter Study on Toxoplasma Gondii in First-episode Schizophrenia</brief_title>
  <official_title>A German Multicenter Study on Toxoplasma Gondii in First-episode Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Martin-Luther-Universität Halle-Wittenberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Martin-Luther-Universität Halle-Wittenberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Environmental risk factors for the development of schizophrenia include infections during the
      perinatal period or later in life with Toxoplasma gondii (TG) being one of the candidate
      agents. A recent review (Torrey and Yolken, 2003) on TG in schizophrenia and other serious
      mental disorder reported higher antibodies to TG in patients compared to controls in 18 of 19
      studies, one having been conducted by the investigators group. In a second, independent study
      on first-episode schizophrenia (n=56) and control subjects (n=32), sera were sampled and
      standard instruments used to assess diagnoses and psychopathology, respectively to screening
      controls.

      For the total sample, contacts with animals during pregnancy and age emerged as a
      non-significant predictors of TG IgG titers. Means of patients' and controls' TG IgG titers
      did not differ significantly but variances did; a subgroup of patients' titers reached much
      higher levels than those of controls. Patients in the high TG IgG subgroup were older
      (p=0.001), also they were older when psychiatric symptoms appeared, more individuals had
      regular animal contacts during pregnancy, or rural upbringing including regular animal
      contact, more consumption of raw meat, and a higher absolute treatment response (all trend
      levels). Regarding the short term course of patients, the investigators detected decreasing
      IgG titers in several individuals A power analysis demonstrated that results fell short of
      significance due to lack of statistical power. Based on the power analysis, the investigators
      propose an opel label, multicenter study at three regionally different sites within Germany
      (Halle, Hamm, Heidelberg). The investigators intent to study 173 first-episode patients with
      schizophrenia, schizoaffective, and schizophreniform disorder and 173 matched controls.

      The investigators hypothesize that - according to the heterogeneity of the illness - a
      subgroup of patients will exhibit higher TG IgG titers compared to the remaining patients and
      to controls; that this subgroup will have had regular contact with animals during pregnancy
      and early life as well as developmental delays; and that clinical improvement, response to
      treatment, and subjective well-being will run parallel with TG IgG decrease.

      Patients shall be assessed on admission to hospital, at discharge and at 6- and
      12-month-follow-up with respect to TG antibody titers, symptomatology, neuropsychology,
      predictors of outcome, quality of life, and neurological soft signs. In controls two
      assessments shall be performed, 12 months apart. All foreseen assessments will be performed
      using standard measurement instruments with sound reliability and validity such as the SCID
      and the PANSS. Exposure to cats, other warm-blooded life-stock, and raw meat will be assessed
      using a special questionnaire.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2008</start_date>
  <completion_date type="Anticipated">May 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>falling levels of Toxoplasma IgG titers parallel clinical improvement over time, 2 follow-ups at 6 and 12 months are planned</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical improvement; outcome: functioning and psychopathology</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizophreniform Disorder</condition>
  <condition>Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>1: FE</arm_group_label>
    <description>FE = first episode schizophrenia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: CO</arm_group_label>
    <description>CO = age and gender-matched control subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TAU = treatment as usual</intervention_name>
    <description>medication and psychosocial interventions to be chosen by treating psychiatrist</description>
    <arm_group_label>1: FE</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum, CSF if patients agree to lumbar puncture all frozen and stored at -80 degree Celsius
      until analysis
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients who are admitted to inpatient treatment due to a first episode of psychotic
        symptoms, diagnoses of schizophrenia, schizophreniform and schizoaffective disorder age-
        and gender-matched control subjects
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Key inclusion criteria will be a first episode of schizophrenia, schizoaffective or
             schizophreniform disorder.

        Exclusion Criteria:

          -  Exclusion criteria will be major organic and substance induced disorders, refusal or
             withdrawal of IC.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silke Bachmann, MD, assistant prof. psychiatry</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Psychiatry, Psychotherapy and Psychosomatics, University of Halle (Saale), Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Silke Bachmann, MD, assistant prof. psychiatry</last_name>
    <phone>49-345-557</phone>
    <phone_ext>3624</phone_ext>
    <email>silke.bachmann@medizin.uni-halle.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Johannes Schroeder, MD, professor of psychiatry</last_name>
    <phone>49-6221-56</phone>
    <phone_ext>4403</phone_ext>
    <email>johannes.schroeder@med.uni-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dpt. of Psychiatry, University of Frankfurt</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>60528</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Pantel, Professor</last_name>
      <phone>+49-69-6301</phone>
      <phone_ext>7094</phone_ext>
      <email>johannes.pantel@kgu.de</email>
    </contact>
    <contact_backup>
      <last_name>Daniela Hainz, MA</last_name>
      <phone>+49-69-6301</phone>
      <phone_ext>7094</phone_ext>
      <email>daniela.hainz@kgu.de</email>
    </contact_backup>
    <investigator>
      <last_name>Johannes Pantel, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniela Hainz, MA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Psychiatry, University of Halle (Saale)</name>
      <address>
        <city>Halle (Saale)</city>
        <zip>06112</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke Bachmann, Deputy Director</last_name>
      <phone>+49-345-557</phone>
      <phone_ext>3624</phone_ext>
      <email>silke.bachmann@medizin.uni-halle.de</email>
    </contact>
    <investigator>
      <last_name>Michaela Beck, MA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Friederike Haupt, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Psychiatry, University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Schroeder, Professor</last_name>
      <phone>+49-6221-56</phone>
      <phone_ext>4403</phone_ext>
      <email>johannes.schroeder@med.uni-heidelberg.de</email>
    </contact>
    <contact_backup>
      <last_name>Kira Krapf, MA</last_name>
      <phone>+49-6221-56</phone>
      <phone_ext>4403</phone_ext>
      <email>kira.krapf@med.uni-heidelberg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Johannes Schroeder, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kira Krapf, MA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.stanleyresearch.org</url>
    <description>The SMRI funds this study, sample analyses wil be made at the Stanley Laboratory of Developmental Neurovirology at the Johns Hopkins University, Baltimore, MD, USA</description>
  </link>
  <reference>
    <citation>Torrey EF, Yolken RH. Toxoplasma gondii and schizophrenia. Emerg Infect Dis. 2003 Nov;9(11):1375-80. Review.</citation>
    <PMID>14725265</PMID>
  </reference>
  <reference>
    <citation>Yolken RH, Bachmann S, Ruslanova I, Lillehoj E, Ford G, Torrey EF, Schroeder J. Antibodies to Toxoplasma gondii in individuals with first-episode schizophrenia. Clin Infect Dis. 2001 Mar 1;32(5):842-4. Epub 2001 Feb 28. Erratum in: Clin Infect Dis 2001 Apr 15;32(8):1247. Rouslanova I [corrected to Ruslanova I].</citation>
    <PMID>11229859</PMID>
  </reference>
  <reference>
    <citation>Bachmann S, Schröder J, Bottmer C, Torrey EF, Yolken RH. Psychopathology in first-episode schizophrenia and antibodies to Toxoplasma gondii. Psychopathology. 2005 Mar-Apr;38(2):87-90. Epub 2005 Apr 22.</citation>
    <PMID>15855832</PMID>
  </reference>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2008</study_first_submitted>
  <study_first_submitted_qc>May 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2008</study_first_posted>
  <last_update_submitted>January 22, 2010</last_update_submitted>
  <last_update_submitted_qc>January 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2010</last_update_posted>
  <responsible_party>
    <name_title>Silke Bachmann, MD</name_title>
    <organization>Dept. of Psychiatry, Psychotherapy and Psychosomatics, University of Halle</organization>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>first-episode</keyword>
  <keyword>infection</keyword>
  <keyword>Toxoplasma gondii</keyword>
  <keyword>levels of IgG antibodies to TG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

